Clinical and genetic determinants of torsade de pointes risk.

Interleukin-1β gene variants are associated with QTc interval prolongation following cardiac surgery: a prospective observational study. Can J Anaesth (2016) 1.39

Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes. Transl Res (2012) 1.25

Long QT syndrome: beyond the causal mutation. J Physiol (2013) 1.00

Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. Circ Res (2015) 0.96

Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil. J Am Heart Assoc (2015) 0.95

Comprehensive analyses of ventricular myocyte models identify targets exhibiting favorable rate dependence. PLoS Comput Biol (2014) 0.91

Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports. Ther Adv Infect Dis (2013) 0.86

Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Healthc Patient Saf (2012) 0.83

Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients. Card Electrophysiol Clin (2016) 0.82

Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol (2015) 0.82

Human-induced pluripotent stem cell models of inherited cardiomyopathies. Curr Opin Cardiol (2014) 0.81

Psychotropic Drugs and Prolonged QTc Interval: Does it Really that Matter? Indian J Psychol Med (2016) 0.78

Human induced pluripotent stem cell-derived versus adult cardiomyocytes: an in silico electrophysiological study on effects of ionic current block. Br J Pharmacol (2015) 0.77

Personalized medicine and atrial fibrillation: will it ever happen? BMC Med (2012) 0.76

Multifactorial QT Interval Prolongation and Takotsubo Cardiomyopathy. Case Rep Cardiol (2014) 0.75

Cardiovascular considerations in antidepressant therapy: an evidence-based review. J Tehran Heart Cent (2013) 0.75

Letter by Sacha regarding article, "clinical and genetic determinants of torsade de pointes risk". Circulation (2012) 0.75

Hypokalemia in women and methadone therapy are the strongest non-cardiologic factors associated with QT prolongation in an emergency department setting. J Electrocardiol (2017) 0.75

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med (1991) 13.91

Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med (2010) 9.19

Sudden cardiac death in the United States, 1989 to 1998. Circulation (2001) 7.92

Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation (2000) 7.50

A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet (2006) 6.39

Modelling the long QT syndrome with induced pluripotent stem cells. Nature (2011) 5.68

Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol (2006) 5.39

Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet (2009) 5.20

Diagnostic criteria for the long QT syndrome. An update. Circulation (1993) 4.48

Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science (2002) 4.40

Prevalence of the congenital long-QT syndrome. Circulation (2009) 4.32

Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation (1998) 4.13

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation (2004) 4.13

Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature (2011) 4.10

Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet (2009) 4.10

Long QT syndrome. J Am Coll Cardiol (2008) 4.08

The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol (1999) 3.57

Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53

Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA (2005) 3.51

Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49

Sudden death in the young. Heart Rhythm (2005) 3.29

QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation (1991) 3.25

Low penetrance in the long-QT syndrome: clinical impact. Circulation (1999) 3.14

Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol (1998) 3.13

Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes? Circulation (2003) 3.05

Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med (1994) 3.04

Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA (1993) 3.01

Microvolt T-wave alternans physiological basis, methods of measurement, and clinical utility--consensus guideline by International Society for Holter and Noninvasive Electrocardiology. J Am Coll Cardiol (2011) 3.00

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med (1999) 2.99

Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98

Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93

Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. Circulation (2007) 2.82

KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation (2005) 2.78

Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J (2005) 2.72

A sodium-channel mutation causes isolated cardiac conduction disease. Nature (2001) 2.67

Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation. BMJ (2000) 2.65

Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation (2007) 2.64

Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. J Am Coll Cardiol (2006) 2.59

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA (2007) 2.57

Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations. Circulation (2009) 2.55

Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. Circulation (1998) 2.48

Heart rate-corrected QT interval prolongation predicts risk of coronary heart disease in black and white middle-aged men and women: the ARIC study. J Am Coll Cardiol (2004) 2.46

Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia. J Cardiovasc Electrophysiol (2000) 2.38

Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med (2006) 2.37

Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation (2009) 2.31

A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol (2003) 2.28

Associations between genetic variants in the NOS1AP (CAPON) gene and cardiac repolarization in the old order Amish. Hum Hered (2007) 2.26

Role of SCN5A Y1102 polymorphism in sudden cardiac death in blacks. Circulation (2005) 2.25

Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J (2005) 2.24

QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation (1998) 2.15

Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome. J Cardiovasc Electrophysiol (1999) 2.14

D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome. J Am Coll Cardiol (2009) 2.12

Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA (2006) 2.12

Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation (2001) 2.11

Dispersion of repolarization in canine ventricle and the electrocardiographic T wave: Tp-e interval does not reflect transmural dispersion. Heart Rhythm (2006) 2.10

Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation (2004) 2.09

Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm (2005) 2.07

The association between the length of the QT interval and mortality in the Cardiovascular Health Study. Am J Med (2003) 2.00

NOS1AP is a genetic modifier of the long-QT syndrome. Circulation (2009) 2.00

Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm (2007) 1.93

In vivo validation of the coincidence of the peak and end of the T wave with full repolarization of the epicardium and endocardium in swine. Heart Rhythm (2005) 1.89

T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (Lond) (2003) 1.86

Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circ Res (2005) 1.86

Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation (2002) 1.84

Antipsychotics and the risk of sudden cardiac death. Arch Intern Med (2004) 1.78

In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation. Am J Physiol Heart Circ Physiol (2006) 1.77

Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome. J Am Coll Cardiol (2010) 1.73

T-peak to T-end interval may be a better predictor of high-risk patients with hypertrophic cardiomyopathy associated with a cardiac troponin I mutation than QT dispersion. Clin Cardiol (2002) 1.72

Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J Cardiovasc Pharmacol (2003) 1.71

The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. J Am Coll Cardiol (2007) 1.69

Transmural dispersion of repolarization and ventricular tachyarrhythmias. J Electrocardiol (2004) 1.67

Drug-induced QT dispersion: does it predict the risk of torsade de pointes? J Electrocardiol (2005) 1.62

Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response. Circulation (2006) 1.60

Relationship of common candidate gene variants to electrocardiographic T-wave peak to T-wave end interval and T-wave morphology parameters. Heart Rhythm (2010) 1.58

Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol (1983) 1.58

Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation (2001) 1.57

I(Kr) channel blockade to unmask occult congenital long QT syndrome. Heart Rhythm (2008) 1.56

Association of NOS1AP genetic variants with QT interval duration in families from the Diabetes Heart Study. Diabetes (2008) 1.53

Sudden cardiac death with apparently normal heart. Circulation (2000) 1.52

QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure. Eur Heart J (1999) 1.51

Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall. Circulation (2001) 1.50

Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol (1997) 1.49

Progesterone regulates cardiac repolarization through a nongenomic pathway: an in vitro patch-clamp and computational modeling study. Circulation (2007) 1.48

A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet (2011) 1.48

Postmortem molecular screening in unexplained sudden death. J Am Coll Cardiol (2004) 1.39

Cellular electropharmacology of amiodarone. Cardiovasc Res (1997) 1.38

T peak-Tend interval as an index of transmural dispersion of repolarization. Eur J Clin Invest (2001) 1.35

Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol (2003) 1.35

Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation (2005) 1.32

Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation (1997) 1.31

Four potassium channel mutations account for 73% of the genetic spectrum underlying long-QT syndrome (LQTS) and provide evidence for a strong founder effect in Finland. Ann Med (2004) 1.28

Beat-to-Beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes. J Am Coll Cardiol (2006) 1.25

Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol (2009) 1.25

Genetic variation in NOS1AP is associated with sudden cardiac death: evidence from the Rotterdam Study. Hum Mol Genet (2009) 1.23

Genetic determinants of sudden cardiac death. Circulation (2008) 1.22

Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc Res (2007) 1.15

SNP S1103Y in the cardiac sodium channel gene SCN5A is associated with cardiac arrhythmias and sudden death in a white family. J Med Genet (2002) 1.13

Experimental models of torsade de pointes. Cardiovasc Res (1998) 1.11

Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol (1999) 1.09

High prevalence of four long QT syndrome founder mutations in the Finnish population. Ann Med (2009) 1.08

Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70

Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73

Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10

Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med (2008) 9.83

Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet (2009) 7.27

A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet (2006) 6.39

The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet (2012) 6.15

Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA (2009) 5.52

Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA (2009) 5.22

The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet (2007) 5.02

Conserved noncoding sequences are selectively constrained and not mutation cold spots. Nat Genet (2005) 4.79

Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97

Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88

Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet (2009) 3.80

Genome-wide association study of PR interval. Nat Genet (2010) 3.73

Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55

Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40

Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation (2006) 3.15

Framingham Heart Study 100K Project: genome-wide associations for blood pressure and arterial stiffness. BMC Med Genet (2007) 3.04

Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med Genet (2007) 2.93

Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet (2010) 2.91

Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. Circulation (2007) 2.82

Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet (2010) 2.24

Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension (2008) 2.14

Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J (2009) 2.06

Genome-wide association studies in an isolated founder population from the Pacific Island of Kosrae. PLoS Genet (2009) 2.02

Relation of QRS width in healthy persons to risk of future permanent pacemaker implantation. Am J Cardiol (2010) 1.97

The early repolarization pattern in the general population: clinical correlates and heritability. J Am Coll Cardiol (2011) 1.95

Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet (2013) 1.91

Genome-wide association study of electrocardiographic conduction measures in an isolated founder population: Kosrae. Heart Rhythm (2009) 1.91

Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. Am J Hum Genet (2012) 1.90

Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res (2013) 1.82

Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation (2006) 1.78

Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol (2010) 1.77

Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet (2013) 1.72

Genome-wide association analysis identifies multiple loci related to resting heart rate. Hum Mol Genet (2010) 1.67

Common genetic variants, QT interval, and sudden cardiac death in a Finnish population-based study. Circ Cardiovasc Genet (2011) 1.67

Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals. Am J Cardiol (2011) 1.65

Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study. BMC Med Genet (2007) 1.65

Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol (2011) 1.61

A blood pressure genetic risk score is a significant predictor of incident cardiovascular events in 32,669 individuals. Hypertension (2013) 1.60

Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. Hypertension (2011) 1.60

Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery. Circ Cardiovasc Genet (2009) 1.59

Relationship of common candidate gene variants to electrocardiographic T-wave peak to T-wave end interval and T-wave morphology parameters. Heart Rhythm (2010) 1.58

Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J (2007) 1.55

Combined admixture mapping and association analysis identifies a novel blood pressure genetic locus on 5p13: contributions from the CARe consortium. Hum Mol Genet (2011) 1.54

Genome-wide association studies of the PR interval in African Americans. PLoS Genet (2011) 1.53

Association of NOS1AP genetic variants with QT interval duration in families from the Diabetes Heart Study. Diabetes (2008) 1.53

Genetic basis of blood pressure and hypertension. Trends Genet (2012) 1.51

Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab (2011) 1.50

A common missense variant in the neuregulin 1 gene is associated with both schizophrenia and sudden cardiac death. Heart Rhythm (2013) 1.47

Blood pressure loci identified with a gene-centric array. Am J Hum Genet (2011) 1.44

Plasma copeptin and the risk of diabetes mellitus. Circulation (2010) 1.44

Genetic polymorphisms confer risk of atrial fibrillation in patients with heart failure: a population-based study. Eur J Heart Fail (2012) 1.43

Identification of a sudden cardiac death susceptibility locus at 2q24.2 through genome-wide association in European ancestry individuals. PLoS Genet (2011) 1.38

Multiple biomarkers and the risk of incident hypertension. Hypertension (2007) 1.34

Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab (2011) 1.31

Common genetic variation near the phospholamban gene is associated with cardiac repolarisation: meta-analysis of three genome-wide association studies. PLoS One (2009) 1.28

Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet (2013) 1.27

Genetic variation in NOS1AP is associated with sudden cardiac death: evidence from the Rotterdam Study. Hum Mol Genet (2009) 1.23

Genetic determinants of sudden cardiac death. Circulation (2008) 1.22

Common variants in cardiac ion channel genes are associated with sudden cardiac death. Circ Arrhythm Electrophysiol (2010) 1.22

Atrial natriuretic peptide is negatively regulated by microRNA-425. J Clin Invest (2013) 1.17

Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol (2011) 1.17

High prevalence of four long QT syndrome founder mutations in the Finnish population. Ann Med (2009) 1.08

Clinical correlates and heritability of QT interval duration in blacks: the Jackson Heart Study. Circ Arrhythm Electrophysiol (2009) 1.08

Large-scale candidate gene analysis in whites and African Americans identifies IL6R polymorphism in relation to atrial fibrillation: the National Heart, Lung, and Blood Institute's Candidate Gene Association Resource (CARe) project. Circ Cardiovasc Genet (2011) 1.06

Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol (2009) 1.05

Effect of weight loss after weight loss surgery on plasma N-terminal pro-B-type natriuretic peptide levels. Am J Cardiol (2010) 1.05

QT interval and long-term mortality risk in the Framingham Heart Study. Ann Noninvasive Electrocardiol (2012) 1.04

Common genetic variants associated with sudden cardiac death: the FinSCDgen study. PLoS One (2012) 1.04

Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J Clin Invest (2013) 1.04

Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation (2010) 1.04

Resequencing and clinical associations of the 9p21.3 region: a comprehensive investigation in the Framingham heart study. Circulation (2013) 1.03

Early repolarization pattern in competitive athletes: clinical correlates and the effects of exercise training. Circ Arrhythm Electrophysiol (2011) 1.01

Increased power of mixed models facilitates association mapping of 10 loci for metabolic traits in an isolated population. Hum Mol Genet (2010) 0.98

Novel loci associated with PR interval in a genome-wide association study of 10 African American cohorts. Circ Cardiovasc Genet (2012) 0.97

Heritability, linkage, and genetic associations of exercise treadmill test responses. Circulation (2007) 0.95

Genetic predisposition to higher blood pressure increases coronary artery disease risk. Hypertension (2013) 0.95

Vascular stiffness and genetic variation at the endothelial nitric oxide synthase locus: the Framingham Heart study. Hypertension (2007) 0.94

Impact of ancestry and common genetic variants on QT interval in African Americans. Circ Cardiovasc Genet (2012) 0.94

Genetic polymorphisms for estimating risk of atrial fibrillation in the general population: a prospective study. Arch Intern Med (2012) 0.92

Orthostatic hypotension and novel blood pressure-associated gene variants: Genetics of Postural Hemodynamics (GPH) Consortium. Eur Heart J (2012) 0.92

Genetic variants and blood pressure in a population-based cohort: the Cardiovascular Risk in Young Finns study. Hypertension (2011) 0.91

A common NOS1AP genetic polymorphism is associated with increased cardiovascular mortality in users of dihydropyridine calcium channel blockers. Br J Clin Pharmacol (2008) 0.91

A common variant in the β2-adrenergic receptor and risk of sudden cardiac death. Heart Rhythm (2011) 0.90

Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation. Pharmacogenet Genomics (2009) 0.90

Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea. Pharmacogenet Genomics (2008) 0.90

Electrocardiographic assessment for therapeutic proteins--scientific discussion. Am Heart J (2010) 0.89

Genome-wide association study in humans. Methods Mol Biol (2009) 0.88

Development and application of a longitudinal electrocardiogram repository: the Framingham Heart Study. J Electrocardiol (2012) 0.88

Novel loci associated with increased risk of sudden cardiac death in the context of coronary artery disease. PLoS One (2013) 0.87

On the interpretation of genetic association studies. Eur Heart J (2004) 0.87

Predictive value of electrocardiographic T-wave morphology parameters and T-wave peak to T-wave end interval for sudden cardiac death in the general population. Circ Arrhythm Electrophysiol (2013) 0.86

Blood pressure and human genetic variation in the general population. Curr Opin Cardiol (2010) 0.85

Prevalence of arrhythmia-associated gene mutations and risk of sudden cardiac death in the Finnish population. Ann Med (2013) 0.85

Intracranial aneurysm risk locus 5q23.2 is associated with elevated systolic blood pressure. PLoS Genet (2012) 0.85

Therapeutic hypothermia for cardiac arrest: real-world utilization trends and hospital mortality. J Hosp Med (2012) 0.85